When Clinical Trials Fail to Address Treatment Gaps: The Failure of Niacin-Laropiprant to Reduce Cardiovascular Events
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Introduction: The Heart Protection Study-2-THRIVE trial (official title: A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant) was designed to investigate the effect raising HDL cholesterol (HDL-C) with extended release niacin (ERN) 2 g plus laropiprant (LRPT) 40 mg daily versus placebo on the time to the first major vascular event (composite of nonfatal myocardial infarction [MI], coronary heart disease [CHD] death, stroke, or arterial revascularization) in patients with a history of occlusive arterial disease (MI, ischemic stroke or transient ischemic attack, peripheral arterial disease, or diabetes with other CHD) who were receiving simvastatin 40 mg daily as background therapy.
Methods: Prior to randomization, the trial incorporated a run-in phase in which 42,424 participants received open-label treatment with simvastatin 40 mg daily to achieve a total cholesterol level < 135 mg/dL (3.5 mmol/L) or simvastatin 40 mg/ ...
- Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 506h anniversary review. J Intern Med. 2005;258:94–114. CrossRef
- The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–81. CrossRef
- Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55. CrossRef
- Taylor AJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–7. CrossRef
- Taylor AJ et al. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243–50. CrossRef
- Taylor AJ et al. tended-release niacin or ezetimibe and carotid intima-media thickness. NEJM. 2008;361:2113–22. CrossRef
- Kane JP et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007–12. CrossRef
- Brown G et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. NEJM. 1990;323:1289–98. CrossRef
- Brown GB et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. NEJM. 2001;345:1583–92. CrossRef
- Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of ini- tial cholesterol levels. N Engl J Med. 1998;339:1349–57. CrossRef
- MRC Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22. CrossRef
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143.
- The AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2225–67.
- Rosenson RS. Clinical trials of HDL cholesterol raising therapy: what have we learned about the HDL hypothesis from AIM-HIGH? Curr Atheroscler Rep. 2012;14:190–2. CrossRef
- Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–32. CrossRef
- When Clinical Trials Fail to Address Treatment Gaps: The Failure of Niacin-Laropiprant to Reduce Cardiovascular Events
Current Atherosclerosis Reports
- Online Date
- April 2013
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Cardiovascular events
- Clinical trials
- Industry Sectors